Medical Marijuana Inc. (OTCMKTS:MJNA) Announce Expansion Of AXIM Biotechnologies’ Research Division

Medical Marijuana Inc. (OTCMKTS:MJNA) has announced that AXIM Biotechnologies Inc. (OTCMKTS:AXIM), its investment company, has expanded the research segment via the establishment of an ultra-modern laboratory in San Diego’s biotechnology industry hub.

New lab major milestone for AXIM

The company has also noted that renowned scientist Sergei Svarovsky will head the oncology-focused research group as its Chief Scientific Officer. Stuart Titus, the CEO of Medical Marijuana, indicated that they are delighted to see more innovation from the team that will be led by an experienced and respected researcher in Svarovsky. Stuart added that the new laboratory is a significant milestone for AXIM. It will help Axim, which is the company’s investment division, to bring its research and in-house entirely as well as continue advancing its scientific discoveries at a rapid pace.

Already the new research laboratory of AXIM is equipped fully for the research team to conduct all its research in-house. The lab sits next to some of the largest biotech companies in the world. This is a prime location, and the number of biotechnology companies in the area gives the AXIM the ability to enhance access and speed of research. This is because of the proximity of analytical services, biology equipment, and vital chemistry.

Svarovsky to apply his experience and expertise  to lead the new lab

Dr. Svarovsky will be the Chief Scientific Officer overseeing the new lab and also lead the research and product development initiatives of Sapphire Biotech Inc. He has a Masters in Physical Chemistry from the Novosibirsk State University as well as a Doctorate in Physical Organic Chemistry and also a Master in Business Administration from West Virginia University. Also, he is a research fellow at NIH’s National Cancer Institute and has received the NIH Fellow Award for Research Excellence through his novel innovations.

John Huemoeller II, the CEO of AXIM Biotech, indicated that the company has recently moved to become an oncology-focused company. He added that through the new lab and Svarovsky’s experience, they hope to bring state or the art research resources to the company’s research team and continue advancing discoveries.

Related Posts

About The Author

Add Comment